

JRHS

Journal of Research in Health Sciences

journal homepage: www.umsha.ac.ir/jrhs



Original Article

Predictors of Adherence to Type 2 Diabetes Medication

Azar Pirdehghan (MD)^{a*}, Nafise Poortalebi (MD)^b

- ^a Department of Community and Preventive Medicine, School Of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
- ^b Department of Community and Preventive Medicine, School Of Medicine, University of Shahid Sadoughi, Yazd, Iran

ARTICLE INFORMATION

Article history:

Received: 16 March 2016 Revised: 18 April 2016 Accepted: 13 May 2016 Available online: 20 May 2016

Keywords:

Diabetes Mellitus Adherence Diabetes Medication Adherence Health Beliefs

* Correspondence

Azar Pirdehghan (MD) Tel: +98 81 38380572

Email: pirdehghan93@gmail.com

ABSTRACT

Background: Despite the effectiveness of drug therapy in diabetes management high rates of poor adherence persist. The purpose of this study was to determine the factors influencing the medication adherence and dietary regiment in type2 diabetic patients.

Methods: This cross sectional study was conducted on 300 type2 diabetic patients referred to General Internal Medicine Clinic, Yazd Shohdaye Kargar Hospital, Yazd City, central Iran between September and December 2013. Each consented participant was interviewed by a trained study member using a questionnaire in three sections: Socio-demographic questions, self-reported Morisky medication adherence scale and Disease and medication beliefs Patient's questionnaire. Multivariable logistic regression model was developed to identify independent predictors of poor adherence. *P*<0.05 was considered statistically significant.

Results: Patients had diabetes for an average of 8.87 (SD: 6.0) yr with a mean age of 58.22 (SD: 10.27) yr. Totally, 101(33.7%) of the patients reported poor adherence with their diabetes medication. In multivariate analyses, good familial support (OR=0.11; 0.03, 0.37), and tendency to consume sweets (OR=1.21; 1.05, 1.39), belief about medication (OR=0.02; 0.018, 0.07) and tendency to consume vegetables (OR=0.75; 0.65, 0.88) were considered as predictive factors for poor adherence.

Conclusions: Familial support, belief about medication, tendency to consume sweets and vegetables are logical goals for educational interventions to modify diabetes self-management.

Citation:

Pirdehghan A, Poortalebi N. Predictors of Adherence to Type2 Diabetes Medication. J Res Health Sci. 2016; 16(2):72-75.

Introduction

iabetes is one of the most increasing common public health issues globally. This disease known to be the fifth cause of mortality in the western societies¹ and fourth reason of referring to the physicians, has been allocated 15% of health care costs in the USA².

The incidence rate of diabetes type 2 is increasing in the world which can be due to life style change resulting in obesity and reduction of physical activity. The incidence of diabetes in Iran is accounted for 14% in the population over 30³. Training diabetic patients along with adherence allows the patients to take more responsibility to care themselves⁴. Adherence is the amount of acceptance and adaptability with caregivers' advice⁵. According to WHO, adherence includes the change in individual's behavior, drug administration, regiment follow-up, life style change and application of caregivers' advice⁶. For 36%-93% of cases, medication adherence by diabetic type 2 patients is not satisfactory. There have been some discussions about the effects of weak adherence such as weak control of blood sugar and preventable hospitalization in chronic diseases such as diabetes and blood pressure⁸⁻¹⁰.

Different studies have mentioned several factors low of medication adherence such as the number of administered medications, complexity of treatment regiment, comorbidity, weak family support and inaccessibility to medication or lack of insurance coverage for the required drugs^{6,11-13}.

Regarding the importance of adherence in management of diabetic patients, we aimed to determine the factors influencing the medication adherence and dietary regiment in type 2 diabetic patients so that there can be suggested some strategies to plan interventions.

Methods

This cross sectional was study in non-randomized sampling method conducted on 300 type2 diabetic patients referred for control and complication follow up. After Institutional Review Board approval, study participants were recruited from General Internal Medicine Clinic, Yazd Shohdaye Kargar Hospital, Yazd City between September and December 2013. Trained staff identified patients using a list of adults with diabetes coming in for visits each day and approached these potential participants in the waiting room. All 30- yr- old or older patients reporting a history of type 2 diabetes for at least 12 months prescribed diabetes medication were enrolled. Exclusion criteria included patient who refused insulin therapy recommendation and stayed on drugs for different reasons.

Each consented participant was interviewed by a trained study member using a questionnaire in three sections: Sociodemographic questions, self-reported Morisky medication adherence scale and Disease and medication beliefs Patient's questionnaire.

Socio-demographic factors, diabetes history, and co morbidities (medical and psychiatric) were self-reported. The primary outcome measure of adherence to diabetes medicines was determined using a modified version of the six items, self-reported Morisky medication adherence scale ¹⁴. Each item is in a yes/no format with possible score of four to six, equating good adherence and zero to three typically considered as poor adherence. The Morisky scale has been used across many chronic diseases, including diabetes, as a self-reported measure of adherence to medications and has demonstrated good reliability and predictive validity ¹⁵⁻¹⁷. In present study, it had proper reliability (Cronbach alpha: necessity=0.70).

Disease and medication beliefs Patient's disease beliefs were measured with 19 item assessing beliefs about the chronicity, cause, consequences and controllability of their diabetes using the Brief-Illness Perception Questionnaire (test–retest reliability across domains (0.42 to 0.72) as a framework ¹⁸.

Medication beliefs were assessed using the five items of greatest relevance to diabetes medication adapted from the Beliefs about Medicines Questionnaire (Cronbach alpha: necessity=0.74, concerns=0.80)¹⁹.

Additional questions assessed familial support and access to medicine in tree scale (poor, moderate and good) and tendency to eat fruits vegetables, meat and sweetmeat in score rang 1 to 10.

Categorical variables are reported as percentages and continuous variables as means. Socio-demographics, medical history, beliefs and knowledge rates were calculated using descriptive statistics. The final multivariable logistic regression model was developed to identify independent predictors of poor adherence based on the variables associated with adherence in the univariate analysis using a Forward conditional model. All statistical analyses were performed using SPSS.19 statistical software (Chicago, IL, USA). *P*<0.05 was considered statistically significant.

Results

The 300 study subjects were all clinic attending patients with type 2 diabetes of age between 30 and 85 yr. More than 50% of participants had longstanding diabetes (7 yr and more) and more participants were on medications included in glibenclamide or metformin.

Respondents reported high levels of co morbid conditions (hypertension 189 (63%) and hyperlipidemia 171 (57%)) commonly associated with diabetes (Table1). Totally, 101 (33.7%) of patients reported poor adherence with their diabetes medication.

Among demographic and clinical variables analyzed, being single or divorced, drug medication versus insulin therapy, younger age and lower duration of disease had a significant relationship with poor adherence in diabetic patients (P<0.05) (Table 1 and 2).

Table 1: Socio-demographic and clinical characteristics of study patients (n=300)

Categorical variables Fine adherence Poor adherence P value Gender 78 (70.3) 33 (29.7) 0.269 Female 78 (70.3) 33 (29.7) 0.007 Male 121 (64.0) 68 (36.0) 0.007 Marital status 0.007 0.007 Married 180 (69.2) 80 (30.8) 0.007 Married 180 (69.2) 80 (30.8) 0.007 Married 180 (69.2) 80 (30.8) 0.049 Single or divorce 19 (47.5) 21 (52.5) 0.490 University education 15 (32.6) 0.490 Yes 31 (67.4) 15 (32.6) 0.0490 Yes 45 (77.6) 13 (22.4) 0.0043 Yes 45 (77.6) 13 (22.4) 0.003 Insulin 46 (78.0) 13 (22.0) 0.003 Insulin 46 (78.0) 13 (22.0) 0.054 Yes 133 (70.4) 56 (29.6) 0.054 Yes 133 (70.4) 56 (29.6) 0.0378 <	(11=300)			
Gender 78 (70.3) 33 (29.7) Male 121 (64.0) 68 (36.0) Marital status 0.007 Married 180 (69.2) 80 (30.8) Single or divorce 19 (47.5) 21 (52.5) University education 0.490 Yes 31 (67.4) 15 (32.6) No 168 (66.1) 86 (33.9) Family history of diabetes 0.043 Yes 45 (77.6) 13 (22.4) No 154 (63.6) 88 (36.4) Medication type 0.003 Insulin 46 (78.0) 13 (22.0) Drug 153 (64.6) 84 (35.4) Hypertension 0.054 Yes 133 (70.4) 56 (29.6) No 66 (59.5) 45 (40.5) Hyperlipidemia 0.378 Yes 117 (68.4) 54 (31.6) No 82 (63.6) 47 (36.4)		Fine adherence	Poor adherence	
Female Male 78 (70.3) 33 (29.7) Male 121 (64.0) 68 (36.0) Marital status 0.007 Married 180 (69.2) 80 (30.8) Single or divorce 19 (47.5) 21 (52.5) University education 0.490 Yes 31 (67.4) 15 (32.6) No 168 (66.1) 86 (33.9) Family history of diabetes 0.043 Yes 45 (77.6) 13 (22.4) No 154 (63.6) 88 (36.4) Medication type 0.003 Insulin 46 (78.0) 13 (22.0) Drug 153 (64.6) 84 (35.4) Hypertension 0.054 Yes 133 (70.4) 56 (29.6) No 66 (59.5) 45 (40.5) Hyperlipidemia 0.378 Yes 117 (68.4) 54 (31.6) No 82 (63.6) 47 (36.4) Continuous variables Mean (SD) Mean (SD) P value	Categorical variables	Number (%)	Number (%)	P value
Male 121 (64.0) 68 (36.0) Marital status 0.007 Married 180 (69.2) 80 (30.8) Single or divorce 19 (47.5) 21 (52.5) University education 0.490 Yes 31 (67.4) 15 (32.6) No 168 (66.1) 86 (33.9) Family history of diabetes 0.043 Yes 45 (77.6) 13 (22.4) No 154 (63.6) 88 (36.4) Medication type 0.003 Insulin 46 (78.0) 13 (22.0) Drug 153 (64.6) 84 (35.4) Hypertension 0.054 Yes 133 (70.4) 56 (29.6) No 66 (59.5) 45 (40.5) Hyperlipidemia 0.378 Yes 117 (68.4) 54 (31.6) No 82 (63.6) 47 (36.4) Continuous variables Mean (SD) Mean (SD) P value	Gender			0.269
Marital status 0.007 Married 180 (69.2) 80 (30.8) Single or divorce 19 (47.5) 21 (52.5) University education 0.490 Yes 31 (67.4) 15 (32.6) No 168 (66.1) 86 (33.9) Family history of diabetes 0.043 Yes 45 (77.6) 13 (22.4) No 154 (63.6) 88 (36.4) Medication type 0.003 Insulin 46 (78.0) 13 (22.0) Drug 153 (64.6) 84 (35.4) Hypertension 0.054 Yes 133 (70.4) 56 (29.6) No 66 (59.5) 45 (40.5) Hyperlipidemia 0.378 Yes 117 (68.4) 54 (31.6) No 82 (63.6) 47 (36.4) Continuous variables Mean (SD) Mean (SD) P value	Female	78 (70.3)	33 (29.7)	
Married 180 (69.2) 80 (30.8) Single or divorce 19 (47.5) 21 (52.5) University education 0.490 Yes 31 (67.4) 15 (32.6) No 168 (66.1) 86 (33.9) Family history of diabetes 0.043 Yes 45 (77.6) 13 (22.4) No 154 (63.6) 88 (36.4) Medication type 0.003 Insulin 46 (78.0) 13 (22.0) Drug 153 (64.6) 84 (35.4) Hypertension 0.054 Yes 133 (70.4) 56 (29.6) No 66 (59.5) 45 (40.5) Hyperlipidemia 0.378 Yes 117 (68.4) 54 (31.6) No 82 (63.6) 47 (36.4) Continuous variables Mean (SD) Mean (SD) P value	Male	121 (64.0)	68 (36.0)	
Single or divorce 19 (47.5) 21 (52.5) University education 0.490 Yes 31 (67.4) 15 (32.6) No 168 (66.1) 86 (33.9) Family history of diabetes 0.043 Yes 45 (77.6) 13 (22.4) No 154 (63.6) 88 (36.4) Medication type 0.003 Insulin 46 (78.0) 13 (22.0) Drug 153 (64.6) 84 (35.4) Hypertension 0.054 Yes 133 (70.4) 56 (29.6) No 66 (59.5) 45 (40.5) Hyperlipidemia 0.378 Yes 117 (68.4) 54 (31.6) No 82 (63.6) 47 (36.4) Continuous variables Mean (SD) Mean (SD)	Marital status			0.007
University education 0.490 Yes 31 (67.4) 15 (32.6) No 168 (66.1) 86 (33.9) Family history of diabetes 0.043 Yes 45 (77.6) 13 (22.4) No 154 (63.6) 88 (36.4) Medication type 0.003 Insulin 46 (78.0) 13 (22.0) Drug 153 (64.6) 84 (35.4) Hypertension 0.054 Yes 133 (70.4) 56 (29.6) No 66 (59.5) 45 (40.5) Hyperlipidemia 0.378 Yes 117 (68.4) 54 (31.6) No 82 (63.6) 47 (36.4) Continuous variables Mean (SD) Mean (SD) P value	Married	180 (69.2)	80 (30.8)	
Yes 31 (67.4) 15 (32.6) No 168 (66.1) 86 (33.9) Family history of diabetes 0.043 Yes 45 (77.6) 13 (22.4) No 154 (63.6) 88 (36.4) Medication type 0.003 Insulin 46 (78.0) 13 (22.0) Drug 153 (64.6) 84 (35.4) Hypertension 0.054 Yes 133 (70.4) 56 (29.6) No 66 (59.5) 45 (40.5) Hyperlipidemia 0.378 Yes 117 (68.4) 54 (31.6) No 82 (63.6) 47 (36.4) Continuous variables Mean (SD) Mean (SD) P value	Single or divorce	19 (47.5)	21 (52.5)	
No 168 (66.1) 86 (33.9) Family history of diabetes 0.043 Yes 45 (77.6) 13 (22.4) No 154 (63.6) 88 (36.4) Medication type 0.003 Insulin 46 (78.0) 13 (22.0) Drug 153 (64.6) 84 (35.4) Hypertension 0.054 Yes 133 (70.4) 56 (29.6) No 66 (59.5) 45 (40.5) Hyperlipidemia 0.378 Yes 117 (68.4) 54 (31.6) No 82 (63.6) 47 (36.4) Continuous variables Mean (SD) Mean (SD) P value	University education			0.490
Family history of diabetes 0.043 Yes 45 (77.6) 13 (22.4) No 154 (63.6) 88 (36.4) Medication type 0.003 Insulin 46 (78.0) 13 (22.0) Drug 153 (64.6) 84 (35.4) Hypertension 0.054 Yes 133 (70.4) 56 (29.6) No 66 (59.5) 45 (40.5) Hyperlipidemia 0.378 Yes 117 (68.4) 54 (31.6) No 82 (63.6) 47 (36.4) Continuous variables Mean (SD) Mean (SD) P value	Yes	31 (67.4)	15 (32.6)	
Yes 45 (77.6) 13 (22.4) No 154 (63.6) 88 (36.4) Medication type 0.003 Insulin 46 (78.0) 13 (22.0) Drug 153 (64.6) 84 (35.4) Hypertension 0.054 Yes 133 (70.4) 56 (29.6) No 66 (59.5) 45 (40.5) Hyperlipidemia 0.378 Yes 117 (68.4) 54 (31.6) No 82 (63.6) 47 (36.4) Continuous variables Mean (SD) Mean (SD)	No	168 (66.1)	86 (33.9)	
No 154 (63.6) 88 (36.4) Medication type 0.003 Insulin 46 (78.0) 13 (22.0) Drug 153 (64.6) 84 (35.4) Hypertension 0.054 Yes 133 (70.4) 56 (29.6) No 66 (59.5) 45 (40.5) Hyperlipidemia 0.378 Yes 117 (68.4) 54 (31.6) No 82 (63.6) 47 (36.4) Continuous variables Mean (SD) Mean (SD) P value	Family history of diabetes			0.043
Medication type 0.003 Insulin 46 (78.0) 13 (22.0) Drug 153 (64.6) 84 (35.4) Hypertension 0.054 Yes 133 (70.4) 56 (29.6) No 66 (59.5) 45 (40.5) Hyperlipidemia 0.378 Yes 117 (68.4) 54 (31.6) No 82 (63.6) 47 (36.4) Continuous variables Mean (SD) Mean (SD) P value	Yes	45 (77.6)	13 (22.4)	
Insulin 46 (78.0) 13 (22.0) Drug 153 (64.6) 84 (35.4) Hypertension 0.054 Yes 133 (70.4) 56 (29.6) No 66 (59.5) 45 (40.5) Hyperlipidemia 0.378 Yes 117 (68.4) 54 (31.6) No 82 (63.6) 47 (36.4) Continuous variables Mean (SD) Mean (SD)	No	154 (63.6)	88 (36.4)	
Drug 153 (64.6) 84 (35.4) Hypertension 0.054 Yes 133 (70.4) 56 (29.6) No 66 (59.5) 45 (40.5) Hyperlipidemia 0.378 Yes 117 (68.4) 54 (31.6) No 82 (63.6) 47 (36.4) Continuous variables Mean (SD) Mean (SD) P value	Medication type			0.003
Hypertension 0.054 Yes 133 (70.4) 56 (29.6) No 66 (59.5) 45 (40.5) Hyperlipidemia 0.378 Yes 117 (68.4) 54 (31.6) No 82 (63.6) 47 (36.4) Continuous variables Mean (SD) Mean (SD) P value	Insulin	46 (78.0)	13 (22.0)	
Yes 133 (70.4) 56 (29.6) No 66 (59.5) 45 (40.5) Hyperlipidemia 0.378 Yes 117 (68.4) 54 (31.6) No 82 (63.6) 47 (36.4) Continuous variables Mean (SD) Mean (SD) P value	Drug	153 (64.6)	84 (35.4)	
No 66 (59.5) 45 (40.5) Hyperlipidemia 0.378 Yes 117 (68.4) 54 (31.6) No 82 (63.6) 47 (36.4) Continuous variables Mean (SD) Mean (SD) P value	Hypertension			0.054
Hyperlipidemia 0.378 Yes 117 (68.4) 54 (31.6) No 82 (63.6) 47 (36.4) Continuous variables Mean (SD) Mean (SD) P value	Yes	133 (70.4)	56 (29.6)	
Yes 117 (68.4) 54 (31.6) No 82 (63.6) 47 (36.4) Continuous variables Mean (SD) Mean (SD) P value	No	66 (59.5)	45 (40.5)	
No 82 (63.6) 47 (36.4) Continuous variables Mean (SD) Mean (SD) P value	Hyperlipidemia			0.378
Continuous variables Mean (SD) Mean (SD) P value	Yes	117 (68.4)	54 (31.6)	
	No	82 (63.6)	47 (36.4)	
Age (yr) 59.42 (10.01) 55.84 (10.39) 0.004	Continuous variables	Mean (SD)	Mean (SD)	P value
	Age (yr)	59.42 (10.01)	55.84 (10.39)	0.004
Diabetes duration (yr) 9.78 (6.24) 7.07 (5.05) 0.001	Diabetes duration (yr)	9.78 (6.24)	7.07 (5.05)	0.001

Table 2: The comparison of Morisky score between different situation of some familial environment adherence related factors

Variables	Number (%)	Morisky Mean (SD)	P value
Familial support			0.001
Poor	28 (9.3)	2.57 (1.57)	
Moderate	74 (24.6)	3.68 (1.83)	
Fine	198 (66.0)	4.17 (1.56)	
Effects of family disease related advises			
Poor	29 (9.6)	2.30 (1.89)	
Moderate	72 (24.0)	3.86 (1.75)	
Fine	197 (65.6)	4.14 (1.53)	
Accessibility to medications			
Poor	10 (3.3)	2.40 (1.64)	
Moderate	62 (20.6)	3.22 (1.91)	
Fine	225 (75.0)	4.15 (1.55)	

Across some social factors, poor familial support, family disease related advises and insufficient accessibility to medications were significant related agents with poor adherence (P<0.05) (Table 2).

Based on the results of simple logistic regression, significantly related risk variables for "poor adherence", were candidate as to enter in the multivariate analysis model. Among them poor familial support and tendency to consume sweets were considered as predicting and belief about medication and tendency to consume vegetables as protective factors (Table 3).

Table 3: Logistic regression analysis of the relationship between poor adherence and risk variables based on forward conditional procedures

Variables	Odd ratio (95% CI)	P value
Familial support		
Poor	1.00	
Moderate	0.21 (0.06, 0.70)	0.011
Good	0.11 (0.03, 0.37)	0.001
Tendency to consume sweets	1.21 (1.05, 1.39)	0.009
Tendency to consume vegetables	0.75 (0.65, 0.88)	0.001
Belief about medication	0.02 (0.01, 0.07)	0.001

Discussion

66.3% of patients had acceptable medication adherence. These were varied in other studies. For example, in Malaysia, aiming to investigate the medication adherence and the factors related to non-adherence to treatment on 557 type 2 diabetic patients, 53% of patients had unfavorable medication adherence²⁰. In another study in France, aiming to evaluate self-reporting medication adherence and factors related to weak medication adherence on type 2 diabetic patients, 12% of patients had weak medication adherence, 49% medium and 39% had good adherence²¹.

The difference of results in studies can be related to the design of studies, demographic differences of the subjects, different methods in investigating medication adherence and different situation of training patients. In our study, the frequency of patients under study along with unfavorable medication adherence was underestimated due to the following reasons: First, the determination of medication adherence was based on asking the patients, therefore, some patients might answer the questions in favor of the interviewer making the medication adherence unreal. Second, the probability of volunteer bias must have been considered in our study. Surely, those who regularly refer to control blood sugar and visit the physician in health centers have better medication adherence at home and apply the physicians' advice. Some others who are not included in our study due to non-referral to health centers had less medication adherence.

In this study, there was a significant difference between the time of diabetes diagnosis and age with medication adherence in that age group over 75 yr showed higher adherence than other groups. In a study in Tehran, on type 2 diabetic patients for their medication adherence in the last month and their awareness of diabetes, symptoms and attitude on the necessity of medication, subjects over 45 yr showed higher medication adherence²².

Some studies have regarded the medication adherence in patients over 75 yr due to the memory disorder and movement, visual and depression disorder lower than the younger ones inconsistent with our study²³. The significant relationship between age and medication adherence in our study is due to the fact that the elderly see themselves more vulnerable to death, dependency on the family and the symptoms of disability.

In this study, there was a significant relationship between marital status and medication adherence so that the married subjects showed greater adherence than two other groups, as consistent with another study²⁴.

In present study, there was a significant relationship between medication adherence with marital status, family support and access to drug in that medication adherence in subjects with good family support and access to drug was remarkably greater. In another study, factors related to weak medication adherence in patients over 45 yr were lack of family support and weak access to drug²¹. In England, nonsupportive behaviors of family were related to weak diabetic medication adherence and reduced lowering blood sugar²⁵.

Our results showed that in subjects believing the disease and stronger treatment, the medication adherence was greater. False belief was the barrier in control and behavior management and consequently the weak medication adherence of patients²⁶.

In this study, there was a significant relationship between medication adherence and dietary regiment with patient's efficaciosity to family members' advice to suitable regiment in that they had more adherence. In Botswana, lack of admission of advice related food regiment and sports led to non-admission of food regiment and disease exacerbation, as consistent with the present study²⁷.

Our results should be viewed with consideration of limitations. While our study population was only the patients who referred to general internal medicine clinic in order to follow the complications of their disease, the generalizability of our observations to other settings is unknown, and should be explored in future work. And maybe in our research more number of sample sizes could detect weaker associations.

Conclusions

More than 30% of diabetic patients had unacceptable adherence. In multivariate analyses, poor familial support, and tendency to consume sweets were considered as predicting and belief about medication and tendency to consume vegetables as protective factors. Maybe the mention above could be considered as logical goals for educational interventions to modify diabetes self-management in future

Acknowledgments

We gratefully acknowledge all health professionals staff in Yazd Shohdaye Kargar Hospital General Internal Medicine Clinic that helped for data collection.

Conflict of interest statement

The authors declare that have no conflict of interests.

Highlights

- More than 30% of diabetic patients had unacceptable adherence.
- Poor familial support is a predicting factor for poor adherence in diabetic patients.
- Medication belief is a protective factor for poor adherence in diabetic patients.

References

- Beulens JW, Grobbee DE, Nealb B. The global burden of diabetes and its complications: an emerging pandemic. Eur J Cardiovasc Prev Rehabil. 2010;17(1 suppl):S3-S8.
- 2. Andersen R, Newman JF. Societal and individual determinants of medical care utilization in the United States. Milbank Q. 2005;83(4):1-
- 3. Baghianimoghadam M, Afkhami Ardekani M. The effect of educational intervention on quality of life of diabetic patients type 2, referee to diabetic research centre of Yazd. Health Horiz. 2008;13(4):21-28.
- Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427-2443.
- Mulvaney SA, Hood KK, Schlundt DG, Osborn CY, Johnson KB, Rothman RL, et al. Development and initial validation of the barriers to

- diabetes adherence measure for adolescents. Diabetes Res Clin Pract. 2011;94(1):77-83.
- Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27(5):1218-1224.
- Grant RW, Devita NG, Singer DE, Meigs JB. Polypharmacy and medication adherence in patients with type 2 diabetes. *Diabetes Care*. 2003;26(5):1408-1412.
- Rozenfeld Y, Hunt JS, Plauschinat C, Wong KS. Oral antidiabetic medication adherence and glycemic control in managed care. Am JManag Care. 2008;14(2):71-75.
- Ahmadipour H, Farajzadegan Z, Kachoei A, Pirdehghan A. Secondary prevention by enhancing adherence in diabetic patients. Int J Prev Med. 2010;1(1):50-55.
- 10. Jung O, Gechter JL, Wunder C, Paulke A, Bartel C, Geiger H, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens. 2013;31(4):766-774.
- 11. Stopford R, Winkley K, Ismail K. Social support and glycemic control in type 2 diabetes: a systematic review of observational studies. Patient Educ Couns. 2013;93(3):549-558.
- 12. Dunkley AJ, Bodicoat DH, Greaves CJ, Russell C, Yates T, Davies MJ, et al. Diabetes prevention in the real world: effectiveness of pragmatic lifestyle interventions for the prevention of type 2 diabetes and of the impact of adherence to guideline recommendations a systematic review and meta-analysis. Diabetes Care. 2014;37(4):922-933.
- 13. Krass I, Schieback P, Dhippayom T. Adherence to diabetes medication: a systematic review. *Diabet Med.* 2015;32(6):725-737.
- 14. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67-74.
- 15. Krapek K, King K, Warren SS, George KG, Caputo DA, Mihelich K, et al. Medication adherence and associated hemoglobin A1c in type 2 diabetes. Ann Pharmacother. 2004;38(9):1357-1362.
- 16. Al-Qazaz HK, Hassali MA, Shafie AA, Sulaiman SA, Sundram S, Morisky DE. The eight-item Morisky Medication Adherence Scale MMAS: translation and validation of the Malaysian version. Diabetes Res Clin Pract. 2010;90(2):216-221.

- 17. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens, 2008:10(5):348-354.
- 18. Broadbent E, Petrie KJ, Main J, Weinman J. The brief illness perception questionnaire. J Psychosom Res. 2006;60(6):631-637.
- 19. Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health. 1999;14(1):1-24.
- 20. Ahmad NS, Ramli A, Islahudin F, Paraidathathu T. Medication adherence in patients with type 2 diabetes mellitus treated at primary health clinics in Malaysia. Patient Prefer Adherence. 2013;7:525-530.
- 21. Tiv M, Viel J-F, Mauny F, Eschwege E, Weill A, Fournier C, et al. Medication adherence in type 2 diabetes: the ENTRED study 2007, a French population-based study. PLoS One. 2012;7(3):e32412.
- 22. Fataneh Dabaghian, Sedigheh Soheilikhah, Karbakhsh M. medication adherence in patient with type 2 diabetes admited to Shariati and Imam Khomeini hospital. Payesh Quarterly. 2006;4(2):103-111. [Persian]
- 23. Commission P. Potential Benefits of the National Reform Agenda. SSRN Working Paper Series. 2007.
- 24. Durán-Varela BR, Rivera-Chavira B. Franco-Gallegos Pharmacological therapy compliance in diabetes. Salud Publica Mex. 2001;43(3):233-236.
- 25. Mayberry LS, Osborn CY. Family support, medication adherence, and glycemic control among adults with type 2 diabetes. Diabetes Care. 2012;35(6):1239-1245.
- 26. Mann DM, Ponieman D, Leventhal H, Halm EA. Predictors of adherence to diabetes medications: the role of disease and medication beliefs. J Behav Med. 2009;32(3):278-284.
- 27. Ganiyu AB, Mabuza LH, Malete NH, Govender I, Ogunbanjo GA. Nonadherence to diet and exercise recommendations amongst patients with type 2 diabetes mellitus attending Extension II Clinic in Botswana. Afr J Prim Health Care Fam Med. 2013;5(1):1-6.